Trinity Biotech plc ADR美股招股说明书(2026-03-10版)

Prospectus Supplement No. 3(To Prospectus dated January 23, 2026) TRINITY BIOTECH PLCSecondary offering of up to55,890,900 American Depositary Sharesrepresenting1,117,818,000 Ordinary Shares This prospectus supplement updates and supplements the information contained in the prospectus dated January 23, 2026 (asmay be supplemented or amended from time to time, the “Prospectus”), which forms a part of our Registration Statement on Form F-1, with information contained in our Reports on Form 6-K, which were filed with the Securities and Exchange Commission on March10, 2026 (the “Current Reports”). Accordingly, we have attached the Current Reports to this prospectus supplement. The prospectus, as it may be amended or supplemented from time to time, relates to the offer and resale by the SellingShareholders from time to time of up to 1,117,818,000 Ordinary Shares, represented by up to 55,890,900 ADSs. Our ADSs are listed for trading on the Nasdaq Global Select Market under the symbol “TRIB.” The last reported sale price ofour ADSs on March 9, 2026 was $0.7010. You should read the Prospectus, this prospectus supplement and any additional prospectus supplement or amendmentcarefully before you invest in our securities. Our business and an investment in our ADSs involve significant risks. These risks are described under the caption“Risk Factors” beginning on page 5 of the Prospectus and any other risk factors contained in any applicable prospectussupplement and in the documents incorporated by reference into the Prospectus. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved ofthese securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminaloffense. The date of this prospectus supplement is March 10, 2026. SECURITIES AND EXCHANGE COMMISSIONWashington, D.C.20549 F O R M6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16UNDER THE SECURITIES EXCHANGE ACT OF 1934For the month of March 2026 TRINITY BIOTECH PLC(Name of Registrant) IDA Business ParkBray, Co. Wicklow, Ireland(Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F☒Form 40-F☐ This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279, 333-195232 and 333-253070). EXPLANATORY NOTE On March 10, 2026, the Company issued a press release announcing further major technical breakthroughs in advancing its NextGeneration CGM+ Platform. A copy of the press release is filed herewith as Exhibit 99.1. EXHIBIT INDEX SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed onits behalf by the undersigned, thereunto duly authorized. TRINITY BIOTECH PLCTrinity Biotech plc(Registrant)By: /s/ Paul MurphyPaul MurphyInterim Chief Financial Officer Date:March 10, 2026 CONFIDENTIAL UNTIL RELEASED RedChip Companies Inc.Dave Gentry, CEO(1)-407-644-4256(1)-800-RED-CHIP (733-2447)TRIB@redchip.com Trinity Biotech plcGary Keating, PhD(353)-1-2769800 Contact: Trinity Biotech Announces Further Major TechnicalBreakthroughs in Advancing Next Generation CGM+ Platform - Clinical trial results support progression of CGM+ toward regulatory submissions and scaled commercialization - Anticipating initiation of pivotal clinical trial in 2026 - Updated electronics architecture delivers significant improvement in glucose measurement accuracy, with a materialreduction in MARD across multi-day wear - Multimodal sensing platform powered by advanced AI-native analytics to deliver personalized metabolic health insights - CGM+ next-generation modular device architecture designed to reduce cost and improve sustainability versuscurrent market-leading CGMs - Company is positioning device to participate in fast-growing $15bn CGM market and adjacent sectors DUBLIN, Ireland and OREGON, United States of America (XXXX, 2026) -Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, todayannounced a number of significant technical advancements in the development of its next-generation, finger-stick calibration-freeContinuous Glucose Monitoring (CGM) system, CGM+, marking a major step toward bringing the technology to global markets. John Gillard, Trinity Biotech President & Chief Executive Officer, commented: “These are some of the most important technical advancements to date in our CGM+ development program. The glucose measurementaccuracy gains achieved by the incorporation of key components of our enhanced electronics architecture gives us strong conviction toaccelerate into pivotal trials this year. The fact that these enhanced electronic components also underpin our innovative multi-